---
schema_version: "secwatch.filing_event.v1"
accession: "0001517022-23-000014"
form_type: "8-K"
ticker: "AKBA"
cik: "0001517022"
company_name: "Akebia Therapeutics, Inc."
filed_at: "2023-06-08T23:59:59+00:00"
generated_at: "2026-06-14T04:54:16.133032+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Akebia shareholders elect three directors, approve 2023 stock plan at annual meeting

## Summary
- Class III directors Adrian Adams, Michael Rogers, LeAnne M. Zumwalt elected for three-year terms.
- 2023 Stock Incentive Plan approved: 61.2M for, 22.8M against, 508K abstentions.
- Non-binding advisory vote on executive compensation passed: 59.7M for, 24.2M against.
- Ernst & Young LLP ratified as auditor for FY2023: 116.5M for, 5.2M against.

## SEC filing metadata
- accession: 0001517022-23-000014
- form_type: 8-K
- ticker: AKBA
- cik: 0001517022
- company_name: Akebia Therapeutics, Inc.
- filed_at: 2023-06-08T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1517022/000151702223000014/0001517022-23-000014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1517022/000151702223000014/akba-20230606.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001517022-23-000014
- JSON: https://secwatch.observer/filing/0001517022-23-000014.json
- Plain text: https://secwatch.observer/filing/0001517022-23-000014.txt

## Key facts
- Shareholder Votes
  Akebia Therapeutics, Inc. shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year 2023 at the 2023-12-31 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-12-31
  source text: (iii) The proposal to ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 received the following votes: Votes For: 116,535,030 Votes Against: 5,158,525 Abstentions: 1,383,705
  evidence_url: https://www.sec.gov/Archives/edgar/data/1517022/000151702223000014/0001517022-23-000014-index.htm
- Shareholder Votes
  Akebia Therapeutics, Inc. shareholders approved Election of three Class III directors to serve until the 2026 annual meeting.
  - Proposal: director election
  - Outcome: passed
  source text: The Class III directors elected to the Board, as well as the number of votes for, votes withheld and broker non-votes with respect to each of these individuals, are set forth below: Director Votes For Votes Withheld Broker Non-Votes Adrian Adams 61,064,658 23,449,941 38,562,661 Michael Rogers 64,246,561 20,268,038 38,562,661 LeAnne M. Zumwalt 60,778,528 23,736,071 38,562,661
  evidence_url: https://www.sec.gov/Archives/edgar/data/1517022/000151702223000014/0001517022-23-000014-index.htm
- Shareholder Votes
  Akebia Therapeutics, Inc. shareholders approved Approval of the 2023 Equity Incentive Plan.
  - Proposal: equity plan
  - Outcome: passed
  source text: (ii) The proposal to approve the 2023 Plan received the following votes: Votes For: 61,173,115 Votes Against: 22,833,112 Abstentions: 508,372 Broker Non-Votes 38,562,661
  evidence_url: https://www.sec.gov/Archives/edgar/data/1517022/000151702223000014/0001517022-23-000014-index.htm
- Shareholder Votes
  Akebia Therapeutics, Inc. shareholders approved Advisory vote on executive compensation.
  - Proposal: say on pay
  - Outcome: passed
  source text: (iii) The advisory vote on the compensation of the Company’s named executive officers received the following votes: Votes For: 59,695,038 Votes Against: 24,230,548 Abstentions: 589,013 Broker Non-Votes 38,562,661
  evidence_url: https://www.sec.gov/Archives/edgar/data/1517022/000151702223000014/0001517022-23-000014-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.